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Statement of findings
Destruction of cartilage and bone are hallmarks of human rheumatoid arthritis (RA), and
controlling these erosive processes is the most challenging objective in the treatment of RA.
Systemic interleukin-4 treatment of established murine collagen-induced arthritis
suppressed disease activity and protected against cartilage and bone destruction. Reduced
cartilage pathology was confirmed by both decreased serum cartilage oligomeric matrix
protein (COMP) and histological examination. In addition, radiological analysis revealed
that bone destruction was also partially prevented. Improved suppression of joint swelling
was achieved when interleukin-4 treatment was combined with low-dose prednisolone
treatment. Interestingly, synergistic reduction of both serum COMP and inflammatory
parameters was noted when low-dose interleukin-4 was combined with prednisolone.
Systemic treatment with interleukin-4 appeared to be a protective therapy for cartilage and
bone in arthritis, and in combination with prednisolone at low dosages may offer an
alternative therapy in RA.
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Introduction: Rheumatoid arthritis (RA) is associated with an
increased production of a range of cytokines including
tumour necrosis factor (TNF)-α and interleukin (IL)-1, which
display potent proinflammatory actions that are thought to
contribute to the pathogenesis of the disease. Although TNF-
α seems to be the major cytokine in the inflammatory
process, IL-1 is the key mediator with regard to cartilage and
bone destruction. Apart from direct blockade of IL-1/TNF,
regulation can be exerted at the level of modulatory cytokines
such as IL-4 and IL-10. IL-4 is a pleiotropic T-cell derived
cytokine that can exert either suppressive or stimulatory
effects on different cell types, and was originally identified as
a B-cell growth factor and regulator of humoral immune
pathways. IL-4 is produced by activated CD4+ T cells and it
promotes the maturation of Th2 cells. IL-4 stimulates
proliferation, differentiation and activation of several cell
types, including fibroblasts, endothelial cells and epithelial
cells. IL-4 is also known to be a potent anti-inflammatory
http://arthritis-research.com/26oct99/ar0101p03
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cytokine that acts by inhibiting the synthesis of
proinflammatory cytokines such as IL-1, TNF-α, IL-6, IL-8 and
IL-12 by macrophages and monocytes. Moreover, IL-4
stimulates the synthesis of several cytokine inhibitors such as
interleukin-1 receptor antagonist (IL-1Ra), soluble IL-1-
receptor type II and TNF receptors IL-4 suppresses
metalloproteinase production and stimulates tissue inhibitor
of metalloproteinase-1 production in human mononuclear
phagocytes and cartilage explants, indicating a protective
effect of IL-4 towards extracellular matrix degradation.
Furthermore, IL-4 inhibits both osteoclast activity and survival,
and thereby blocks bone resorption in vitro. Of great
importance is that IL-4 could not be detected in synovial fluid
or in tissues. This absence of IL-4 in the joint probably
contributes to the disturbance in the Th1/Th2 balance in
chronic RA.
Collagen-induced arthritis (CIA) is a widely used model of
arthritis that displays several features of human RA. Recently it
was demonstrated that the onset of CIA is under stringent
control of IL-4 and IL-10. Furthermore, it was demonstrated
that exposure to IL-4 during the immunization stage reduced
onset and severity of CIA. However, after cessation of IL-4
treatment disease expression increased to control values.
Aims: Because it was reported that IL-4 suppresses several
proinflammatory cytokines and matrix degrading enzymes and
upregulates inhibitors of both cytokines and catabolic
enzymes, we investigated the tissue protective effect of
systemic IL-4 treatment using established murine CIA as a
model. Potential synergy of low dosages of anti-inflammatory
glucocorticosteroids and IL-4 was also evaluated.
Methods: DBA-1J/Bom mice were immunized with bovine
type II collagen and boosted at day 21. Mice with established
CIA were selected at day 28 after immunization and treated
for days with IL-4, prednisolone, or combinations of
prednisolone and IL-4. Arthritis score was monitored visually.
Joint pathology was evaluated by histology, radiology and
serum cartilage oligomeric matrix protein (COMP). In addition,
serum levels of IL-1Ra and anticollagen antibodies were
determined.
Results: Treatment of established CIA with IL-4 (1 µg/day)
resulted in suppression of disease activity as depicted in
Figure 1. Of great interest is that, although 1 µg/day IL-4 had
only a moderate effect on the inflammatory component of the
disease activity, it strongly reduced cartilage pathology, as
determined by histological examination (Fig. 1). Moreover,
serum COMP levels were significantly reduced, confirming
decreased cartilage involvement. In addition, both histological
and radiological analysis showed that bone destruction was
prevented (Fig. 1). Systemic IL-4 administration increased
serum IL-1Ra levels and reduced anticollagen type II antibody
levels. Treatment with low-dose IL-4 (0.1 µg/day) was
ineffective in suppressing disease score, serum COMP or joint
destruction. Synergistic suppression of both arthritis severity
and COMP levels was noted when low-dose IL-4 was
combined with prednisolone (0.05 mg/kg/day), however, which
in itself was not effective.
Discussion: In the present study, we demonstrate that
systemic IL-4 treatment ameliorates disease progression of
established CIA. Although clinical disease progression was
only arrested and not reversed, clear protection against
cartilage and bone destruction was noted. This is in accord
with findings in both human RA and animal models of RA that
show that inflammation and tissue destruction sometimes are
uncoupled processes. Of great importance is that, although
inflammation was still present, strong reduction in serum
COMP was found after exposure to IL-4. This indicated that
serum COMP levels reflected cartilage damage, although a
limited contribution of the inflamed synovium cannot be
excluded.
Increased serum IL-1Ra level (twofold) was found after
systemic treatment with IL-4, but it is not likely that this could
explain the suppression of CIA. We and others have reported
that high dosages of IL-1Ra are needed for marked
suppression of CIA. As reported previously, lower dosages of
IL-4 did not reduce clinical disease severity of established CIA.
Of importance is that combined treatment of low dosages of
IL-4 and IL-10 appeared to have more potent anti-inflammatory
effects, and markedly protected against cartilage destruction.
Improved anti-inflammatory effect was achieved with
IL-4/prednisolone treatment. In addition, synergistic effects
were found for the reduction of cartilage and bone destruction.
This indicates that systemic IL-4/prednisolone treatment may
provide a cartilage and bone protective therapy for human RA.
Figure 1
Effects in mice of treatment with interleukin-4 or control on disease
activity, cartilage damage and bone destruction. Mice were treated
intraperitoneally for 7 days with either vehicle (control) or 1 µg/day
interleukin-4 (IL-4). CIA, collagen-induced arthritis. *P < 0.05, versus
control, by Mann–Whitney U test.
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Introduction
Interleukin (IL)-4 is a pleiotropic T-cell-derived cytokine
that can exert either suppressive or stimulatory effects on
different cell types. It was originally identified as a B-cell
growth factor and regulator of humoral immune pathways
[1,2]. IL-4 is produced by activated CD4+ T cells and it
promotes the maturation of Th2 cells. IL-4 inhibits the dif-
ferentiation of naïve T cells to Th1 and cytokine (ie IL-2
and interferon-γ) production by Th1 cells [3]. IL-4 stimu-
lates proliferation, differentiation or activation of several
cell types, including fibroblasts, endothelium cells and
epithelium cells [4]. IL-4 is also known to be a potent anti-
inflammatory cytokine that acts by inhibiting the synthesis
of proinflammatory cytokines such as IL-1, tumour necro-
sis factor (TNF)-α, IL-6, IL-8 and IL-12 by macrophages
and monocytes [5–7]. Moreover, IL-4 stimulates the syn-
thesis of several cytokine inhibitors such as interleukin-1
receptor antagonist (IL-1Ra), IL-1-receptor type II and
TNF receptors [8–10]. IL-4 suppresses metalloproteinase
production and stimulates tissue inhibitor of metallopro-
teinase-1 production in human mononuclear phagocytes
and cartilage explants, indicating a protective effect of IL-4
towards extracellular matrix degradation [11,12]. Further-
more, IL-4 inhibits both osteoclast activity and survival,
and thereby blocks bone resorption in vitro [13,14].
RA is associated with an increased production of a range of
cytokines including TNFα and IL-1, which display potent
proinflammatory actions that are thought to contribute to the
pathogenesis of rheumatoid arthritis (RA) [15,16]. Although
TNF-α seems to be the major cytokine involved in the
inflammatory process, IL-1 is the key mediator with regard
to cartilage and bone destruction [17,18]. Apart from direct
blockade of IL-1/TNF, regulation can be exerted at the
level of modulatory cytokines such as IL-4 and IL-10. Of
great importance is that IL-4 could not be detected in syn-
ovial fluid and tissues [19,20], and this lack of IL-4 is likely
to contribute to the uneven Th1/Th2 balance in chronic RA.
Although having a number of side effects, including osteo-
porosis and reduced adrenal function, glucocorticoids are
potent and commonly used anti-inflammatory agents in
human RA. Glucocorticoids downregulate proinflammatory
cytokine production, such as IL-1 and TNF-α, by
macrophages and monocytes via several mechanisms. One
mechanism is through enhanced IκBα protein synthesis.
IκBα forms inactive cytoplasmic complexes with nuclear
factor-κB, which itself activates many immunoregulatory
genes in response to proinflammatory cytokines [21,22].
Other mechanisms of action that have been reported recently
[23] are downmodulation of histone acetyltransferase and
upregulation of histone deacetyltransferase, which both
affected messenger RNA transcription negatively.
Murine collagen-induced arthritis (CIA) is a widely used
experimental model of arthritis. Neutralization of the
monokines IL-1 and TNF-α before or during onset of
arthritis arrested the development of CIA [24,25]. Expres-
sion of CIA is also under particularly stringent control by
IL-4 and IL-10. Treatment with anti-IL-4/anti-IL-10
shortly before onset accelerated the disease expression
[26]. Furthermore, it was demonstrated that IL-12 plays a
crucial role in the development of CIA, because blockade
of endogenous IL-12 completely prevented onset of the
disease [27]. In accord with these findings, during onset of
CIA predominantly Th1 responses towards collagen type
II were found [28,29]. It has been claimed [30,31] that
IL-4 exposure could induce immune deviation by
enhanced development of Th2-like primary CD4 effector
cells. Several animal studies indicated that IL-4 adminis-
tration, starting just after immunization with the disease-
inducing agent, ameliorated Th1-mediated models of
autoimmune diseases such as diabetes in nonobese
diabetic mice and experimental arthritis [32–34].
In the present study the effects of systemic high dose IL-4
therapy in established CIA were investigated. Further-
more, the potential synergy of combined prednisolone and
IL-4 treatment were examined. We investigated the pro-
tective effect of IL-4 alone or in combination with pred-
nisolone on disease activity as well as cartilage and bone
destruction as determined histologically, radiologically and
by serum measurements of cartilage oligomeric matrix
protein (COMP). Anticollagen type II specific antibodies
and serum IL-1Ra levels were assessed, in order to obtain
an insight into the mechanism of action. The findings
suggest that IL-4 treatment protects against cartilage and
bone destruction, and that combined IL-4/steroid treat-
ment may provide a safe, anti-inflammatory and anti-
destructive therapy in human RA.
Materials and methods
Animals
Male DBA-1/Bom mice were purchased from Bomholdgård
(Ry, Denmark). The mice were housed in filter top cages,
and were given free access to water and food. The mice
were immunized at the age of 10–12 weeks.
Materials
Complete Freund’s adjuvant and Mycobacterium tuberculosis
(strain H37Ra) were obtained from Difco Laboratories
(Detroit, MI, USA). Bovine serum albumin and pred-
nisolone 21-sodium succinate (P-4153) were purchased
from Sigma Chemicals (St Louis, MO, USA). Antimurine
IL-1Ra antibodies (capture MAP-480, detection BAF-480)
were obtained from R&D Systems (Minneapolis, MN,
USA). PolyHRP-streptavidine (M2032) and Caseine
Full article
colloid buffer (M2052) was from CLB (Amsterdam, The
Netherlands). Recombinant murine IL-1Ra was pur-
chased from R&D systems. Recombinant murine IL-4
(6.5×107 U/mg) was kindly provided by Dr S Smith
(Schering-Plough, Kenilworth, NJ, USA).
Collagen preparation
Articular cartilage was obtained from metacarpophalangeal
joints of 1–2 year old cows. Bovine type II collagen was
prepared according to the method of Miller and Rhodes
[35]. It was dissolved in 0.05mol/l acetic acid (5mg/ml)
and stored at –70ºC.
Immunization
Bovine type II collagen was diluted with 0.05mol/l acetic
acid to a concentration of 2mg/ml and was emulsified in
an equal volume of complete Freund’s adjuvant (2mg/ml
MT H37Ra). The mice were immunized intradermally at
the base of the tail with 100µl emulsion (100µg collagen).
At day 21 the animals were boosted with an intra-
peritoneal injection of 100µg collagen type II, diluted in
phosphate-buffered saline (pH7.4).
Assessment of arthritis
Mice were examined for visual appearance of arthritis in
peripheral joints, and scores for severity were given (arthri-
tis score) as previously described [17,18,25–27]. Mice were
considered arthritic when significant changes in redness
and/or swelling were noted in digits or in other parts of the
paws. At later time points ankylosis was also included in
the arthritis score. Clinical severity of arthritis was graded
on a scale of 0–2 for each paw, according to changes in
redness and swelling: 0, no changes; 0.5, significant; 1.0,
moderate; 1.5, marked; and 2.0, maximal swelling and
redness, and later on ankylosis. Arthritis score (mean±stan-
dard deviation) was expressed as cumulative value for all
paws, with a maximum of eight and expressed as percent-
age of the initial score at the beginning of treatment.
Treatment of collagen-induced arthritis with interleukin-4,
prednisolone or interleukin-4/prednisolone
To evaluate the effect of IL-4, prednisolone or the combi-
nation IL-4/prednisolone on established CIA, mice with
CIA were selected at day 28 and divided into groups of at
least 10 mice with similar arthritis scores. Thereafter, mice
were treated twice a day intraperitoneally with IL-4 (0.1 or
1µg/day), prednisolone (0.05mg/kg/day), or with IL-4 and
prednisolone (at the same doses for the noncombined reg-
imens) for each of several days as indicated in the results.
Determination of interleukin-1 receptor antagonist levels
IL-1Ra was measured using enzyme-linked immunosor-
bent assay (ELISA). Briefly, Nunc Maxisorb ELISA plates
(Nunc, Rostilde, Denmark) were coated with capture anti-
bodies (5µg/ml, carbonate buffer, pH9.6, 24h at 4ºC), and
thereafter nonspecific binding sites were blocked with 1%
bovine serum albumin/phosphate-buffered saline–Tween.
Standards and unknown samples were diluted in normal
DBA-1 serum and incubated for 3 h at room temperature.
Biotinylated detection antibodies were added at concentra-
tions of 0.2–0.4µg/ml in 0.5% bovine serum albumin in
phosphate-buffered slaine-Tween for 1.5h at room
temperature. Thereafter plates were incubated with
PolyHRP (0.1µg/ml in 1% caseine colloid buffer) for
45min and orthophenylenediamine (0.8mg/ml) was used
as substrate. Plates were read at 495nm.
Measurement of cartilage oligomeric matrix protein
At the end of the experiments, serum samples were taken
and murine cartilage oligomeric matrix protein (COMP)
levels were determinated using ELISA under similar con-
ditions as those described for the assay for human COMP
[36]. The assay was modified by using rat COMP for
coating the microtitre plates, the standard curve included
in each plate and by using the polyclonal antiserum raised
against rat COMP to detect the antibody [37,38]. A high
cross-reactivity was found to murine COMP [39]. This was
shown by parallel dilution curves of murine sera to the
standard curve prepared with rat COMP, as well as in
experiments in which a dilution of murine serum was
added to the standard curve.
Determination of anticollagen antibodies
Antibodies against bovine type II collagen were examined
by using an ELISA. Titres of total IgG, IgG1 and IgG2a
were measured. Briefly, plates were coated with 10µg
bovine type II, and thereafter nonspecific bindings sites
were blocked with 0.1mol/l ethanolamin (Sigma Chemi-
cals). Serial 1 : 2 dilutions of the sera were added, followed
by incubation with isotype-specific goat antimouse peroxi-
dase (Southern Biotechnology Associates, Birmingham,
AL, USA) and substrate (5-aminosalicyclic acid; Sigma
Chemicals). Plates were read at 492nm. Titres were
expressed as means±standard deviation dilution, which
gives the half maximal value.
Radiological analysis of bone destruction
At the end of the experiments, knee joints were removed
and used for radiological analysis as a measure of bone
destruction. Radiographs were carefully examined using a
stereo microscope, and joint destruction was graded on a
scale from 0 to 5, ranging from no damage, minor bone
destruction observed as one enlightened spot, moderate
changes, two to four spots observed in one area, marked
changes, two to four spots observed in more areas, severe ero-
sions afflicting the joint, complete destruction of joint and/or
new bone formations. Bone destruction was scored on the
femoral head, tibia and patella as described previously [17].
Histology
Mice were killed by ether anaesthesia. Knee joints were
removed and fixed for 4 days in 4% formaldehyde. After
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decalcification in 5% formic acid, the specimens were
processed for paraffin embedding [17,18,25–27]. Tissue
sections (7µm thick) were stained with haematoxylin and
eosin, or safranin O. Histopathological changes were
scored using the following parameters.
Infiltration of cells was scored on a scale from 0 to 3,
depending on the amount of inflammatory cells in the
synovial tissues. Inflammatory cells in the joint cavity
were graded on a scale from 0 to 3 and expressed as
exudate. Cartilage proteoglycan depletion was determined
using safranin O staining. The loss of proteoglycans was
scored on a scale from 0 to 3, ranging from fully stained
cartilage to destained cartilage or complete loss of articular
cartilage. A characteristic parameter in CIA is the progres-
sive loss of articular cartilage. This destruction was sepa-
rately graded on a scale from 0 to 3, ranging from the
appearance of dead chondrocytes (empty lacunae) to com-
plete loss of the articular cartilage. Bone erosion was
scored on a scale ranging from 0 to 3, ranging from no
abnormalities to complete loss of cortical and trabecular
bone of the femoral head and patella. Histopathological
changes in the knee joints were scored in the
patella/femur region on 5 semiserial sections of the joint,
spaced 70µm apart. Scoring was performed on decoded
slides by two observers, as described earlier [17,18,25–27].
Statistical analysis
Differences between experimental groups were tested
using the Mann–Whitney U test, unless otherwise stated.
Results
Amelioration of arthritis score in collagen-induced arthritis
by in vivo treatment of interleukin-4
To investigate effects of in vivo treatment of established
CIA with IL-4, mice that expressed CIA at day 28 after
immunization were injected intraperitoneally with
vehicle, 0.1 or 1 µg IL-4 per day. Figure 2 shows that
administration of 1 µg/day IL-4 results in significant ame-
lioration of the arthritis score, but a lower dosage of
0.1 µg/day IL-4 was without effect. The anti-inflamma-
tory effect of 1 µg/day IL-4 was further illustrated in
Figure 3, in which disease progression is expressed as
change in (∆) disease activity of all individual mice.
Increased severity of CIA score can be seen in animals
treated either with vehicle or 0.1 µg/day IL-4, whereas
significantly decreased disease activity was noted after
treatment with 1 µg/day IL-4. Histology revealed that no
effect was found on the influx of inflammatory cells in
joint tissues of IL-4-treated animals when compared with
the vehicle-treated animals (Table 1).
Interleukin-4 protects against cartilage destruction
Systemic treatment with high-dose IL-4 (1µg/day) signifi-
cantly decreased cartilage destruction, determined as
chondrocyte death and cartilage erosions (Fig. 4, Table 1).
It did not result in a significantly reduced loss of matrix
proteoglycans, as determined by safranin O staining
(Fig. 5, Table 1). It has been demonstrated (data not
shown) that there is a strong correlation between severe
cartilage damage and increased serum COMP levels
during murine CIA. In naïve DBA-1 mice, serum COMP
levels are approximately 4.0µg/ml and COMP levels
http://arthritis-research.com/26oct99/ar0101p03
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Figure 2
Dose dependent suppression of disease activity of collagen-induced
arthritis (CIA) by interleukin (IL)-4 and the combination of
IL-4/prednisolone (Pred). Mice with established CIA were divided into
separate groups of at least 10 mice. Groups were treated
intraperitoneally twice a day with vehicle, IL-4, prednisolone, or
combined IL-4/prednisolone for 8 consecutive days. The data
represent the mean arthritis score, expressed as percentage of initial
value at day 28. Experiments were repeated once with approximately
the same outcome. *P < 0.05, versus vehicle, by Mann–Whitney U test.
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Figure 3
Dose-dependent arrest of disease activity by treatment with interleukin
(IL)-4 and IL-4/prednisolone (Pred). The enhanced disease activity
between days 28 and 35 of each individual mouse is expressed as
change in (∆) disease activity. For treatment protocol, see Fig. 2.
P < 0.05, versus vehicle, by Mann–Whitney U test.
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increased up to 8–12µg/ml in mice with fully established
CIA. Serum COMP levels were determined in the various
groups to identify the protection against severe cartilage
destruction by IL-4. Figure 6 shows that elevated COMP
in CIA were not reduced by treatment with low-dose
IL-4. It is of particular interest, that treatment with high-
dose IL-4 (1µg/day) significantly reduced serum COMP
levels to values found in nonarthritic control animals.
Interleukin-4 protects against bone destruction
Bone destruction, which is a common feature of murine
collagen arthritis, was examined by radiological analysis.
Radiographs of knee joints were taken at the end of the
treatment period. Figure 7 showed that treatment with
1µg/day IL-4 was sufficient to prevent bone destruction,
determined as bone erosions on the head of the femur, the
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Figure 4
Interleukin (IL)-4 treatment reduced cartilage destruction, whereas
IL-4/prednisolone treatment additionally decreased cell influx. (a) Knee
joint from vehicle-treated mouse. Severe cartilage destruction can be
seen. Empty lacunae reflects chondrocyte death as marker of cartilage
destruction, indicated by arrows. (b) Knee joint of a mouse treated
with IL-4 1 µg/kg/day for eight consecutive days. Note the reduced
cartilage destruction and chondrocyte death. (c) Knee joint of vehicle-
treated animal. Note the severe cell influx in synovial tissues and joint
cavity. (d) Knee joint of a mouse treated with IL-4/prednisolone (1 µg
per day/0.05 mg per kg). Note the marked reduction of cell influx. All
specimens were sampled at day 35. P, patella; F, femur; JS, joint
space; C, cartilage; S, synovium. Haematoxylin and eosin staining was
used. Original magnifications: ×200 (a, b) and ×100 (c, d).
Figure 5
Effect of IL-4 or IL-4/prednisolone treatment on matrix proteoglycan
loss. (a) Knee joint of a control naïve mouse. The fully stained cartilage
layers indicate no loss of proteoglycans. (b) Knee joint of an arthritic
mouse treated with vehicle. Note the severe joint inflammation and
complete loss of safranin O staining of the cartilage layers (indicated
by arrows). (c) Mouse treated with IL-4 (1 µg/day). Loss of matrix
proteoglycan can still be seen. (d) Knee joint of a mouse treated with
IL-4/prednisolone (1 µg per day/0.05 mg per kg). Marked reduction in
matrix proteoglycan depletion after combined treatment. For details
see Fig. 4. Safranin O staining, original magnification ×100.
Figure 6
Serum cartilage oligomeric matrix protein (COMP) level as a marker of
cartilage turnover. Suppression of serum COMP was found after
treatment with interleukin (IL)-4 and IL-4/prednisolone (Pred). IL-4
(1 µg/day) and both doses (0.1 µg per day/0.05 mg per kg per day;
and 1 µg per day/0.05 mg per kg per day) of IL-4/prednisolone
reduced serum COMP levels to basic levels as found in nonimmunized
animals (4.2 ± 0.2 µg/ml). The data represent the mean ± standard
deviation COMP level of at least six sera per group. *P < 0.01, versus
vehicle, by Mann–Whitney U test.
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patella and the tibia. Little or no effect was noted after
treatment with low-dose IL-4. Histological analysis of
knee joints corroborated the protective effect of IL-4
(Table 1). Figure 8 (a, c) depicts degradation of patellar
and femural cortical bone by osteoclasts in the vehicle-
treated group, whereas almost no osteoclasts were seen in
the IL-4-treated group (Fig. 8d). 
Combined interleukin-4/prednisolone treatment
We examined potential synergistic effects of IL-4 and
prednisolone, using low-dose prednisolone (0.05mg/kg/day)
and 0.1 or 1µg/day IL-4. Treatment of CIA with
IL-4/prednisolone completely arrested the development
of inflammatory signs of CIA (Figs 2 and 3). Both combi-
nations tested revealed full suppression of disease pro-
gression. In accord with previous observations, mice
treated with 0.05 mg/kg/day prednisolone alone did not
show significant suppression of arthritis. Histology taken
after 7 days of treatment showed enhanced safranin O
staining only in animals treated with IL-4/prednisolone
(1µg per kg/0.05kg daily), indicating reduced depletion of
matrix proteoglycans (Table 1, Fig. 5d). This was in
accord with the marked reduction in joint inflammation, as
can be seen in Figure 4d. Both combinations of IL-4 and
prednisolone reduced serum COMP to values found in
naïve DBA-1 mice. Interestingly, synergistic suppression
of serum COMP was noted after exposure to low-dose
IL-4 and prednisolone (Fig. 6). In contrast to serum
COMP levels, combined IL-4/prednisolone treatment did
not result in synergistic protection against bone destruc-
tion. High-dose IL-4 alone was already highly effective,
and the combination of IL-4 with prednisolone did not
improve the effect further, or was there an adverse effect
of prednisolone (Table 1, Figs 7 and 8b). Treatment of
CIA with 1µg/day IL-4 alone and in combination with
prednisolone (0.05mg/kg/day) for 7 days caused similar
reduction in osteoclast numbers (data not shown).
Effect of interleukin-4, or interleukin-4/prednisolone
treatment on interleukin-1 receptor antagonist and
anticollagen antibody levels
Serum IL-1Ra levels were determined at the end of the
experiments and Table 2 shows a twofold increase after
IL-4 treatment (1µg/day dose). Treatment with 0.1µg/day
IL-4 showed no significant effects on serum IL-1Ra
levels. Prednisolone reduced IL-1Ra levels when com-
pared with vehicle-treated animals. In accord with these
findings, combined IL-4/prednisolone (1µg per day/
0.05mg per kg per day) treatment resulted in lower
IL-1Ra levels than found with IL-4 alone.
Anticollagen antibodies were assayed at the end of treat-
ment period at day 35. The antibody levels increased
http://arthritis-research.com/26oct99/ar0101p03
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Table 1
Effect of prednisolone, interleukin (IL)-4 or IL-4/prednisolone treatment on the joint pathology of collagen-induced arthritis in
mice
Cartilage Proteoglycan Bone
Treatment Dose Infiltrate destruction loss erosion n
Vehicle – 2.3 ± 0.9 2.2 ± 0.9 2.7 ± 1.0 1.9 ± 0.9 20
Prednisolone 0.05 2.1 ± 0.8 2.1 ± 1.2 2.6 ± 0.6 1.7 ± 1.1 20
IL-4 0.1 2.5 ± 0.7 2.5 ± 0.8 2.9 ± 0.3 2.0 ± 0.8 10
IL-4 1 2.0 ± 1.0 1.2 ± 0.8* 2.0 ± 0.7 0.6 ± 0.6* 20
IL-4/prednisolone 0.1/0.05 2.1 ± 0.4 1.6 ± 0.7 2.5 ± 0.8 2.1 ± 0.6 10
IL-4/prednisolone 1/0.05 1.2 ± 0.5* 1.1 ± 0.9* 1.4 ± 0.7* 0.4 ± 0.5* 10
Histopathology scores of arthritic knee joints after treatment with
vehicle, IL-4, prednisolone or the combination of IL-4/prednisolone.
Mice were sacrified and knee joints were used for histology. Histology
was scored as indicated in the Materials and methods section. Mice
were treated twice a day intraperitoneally with either prednisolone
(0.05 mg/kg), or IL-4 (0.1 or 1 µg/day], or IL-4 (at both dosages)
combined with prednisolone (0.05 mg/kg). *P < 0.05, versus vehicle, by
Mann-Whitney U test.
Figure 7
Protection of interleukin (IL)-4 and IL-4/prednisolone (Pred) treatment
on bone destruction. Knee joints were isolated at day 35 and bone
destruction was examined by radiographic analysis. For treatment
scheme see Fig. 2. Erosions were scored on a scale ranging from 0 to
5 on the femur head, tibia and patella. Each group consists of at least
nine knee joints per group. *P < 0.01, versus vehicle, by
Mann–Whitney U test.
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rapidly after clinical expression of CIA around day 28 after
immunization. After IL-4 (1µg/day) treatment for 7 days,
total IgGs levels as well as IgG1 and IgG2a anticollagen type
II antibody levels were lower compared with vehicle
treated animals (Fig. 9). Although all anticollagen type II
antibodies were reduced, IgG2a levels showed the most
prominent reduction, indicating an effect on the Th1 rather
than on the Th2 immune response. No decreased anticolla-
gen type II antibody levels were found after treatment with
low-dose IL-4. The high-dose IL-4/prednisolone regimen
reduced anticollagen type II antibodies to levels similar to
those found after treatment with 1µg/day IL-4.
Discussion
The present study demonstrates clear tissue-protective
effects of IL-4, although IL-4 did not prove to be a very
potent anti-inflammatory cytokine. Both cartilage and
bone erosion were prevented by IL-4 treatment of
established CIA. Combination with low-dose pred-
nisolone enhanced the anti-inflammatory capacity of IL-4.
This might offer an attractive alternative to the use of
high-dose prednisolone, because it can circumvent the
unwanted side effects of the drug, including steroid-
induced osteoporosis.
In previous studies of murine collagen arthritis [17,18,25]
it was shown that TNF-α is important at onset of the
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Table 2
Serum interleukin-1 receptor antagonist (IL-1Ra levels) after
treatment with either interleukin (IL)-4, prednisolone, or
IL-4/prednisolone
Treatment Dose IL-1Ra (pg/ml)
Vehicle – 414 ± 155
IL-4 0.1 386 ± 213
IL-4 1 838 ± 187*
Prednisolone 0.05 326 ± 165
IL-4/prednisolone 0.1/0.05 422 ± 129
1/0.05 499 ± 187
Serum IL-1Ra was determined using enzyme-linked immunosorbent
assay at day 35 after immunization. Mice were treated as indicated in
Table 1. The data represent the mean ± standard deviation of at least
eight mice per group. The sensitivity of the IL-1Ra assay was to within
160 pg/ml. *P < 0.05, versus vehicle, by Mann–Whitney U test.
Figure 9
Interleukin (IL)-4 or IL-4/prednisolone (Pred) treatment is associated
with reduced anticollagen type II (CII) antibody levels. Treatment with
1 µg/day IL-4 resulted in lower anticollagen type II antibodies. Total
Immunoglobulins (Ig tot), IgG1 and IgG2a levels were reduced. Similar
effects were found after treatment with IL-4/prednisolone (1 µg per
day/0.05 mg per kg). Anticollagen type II levels were determined in at
least six mice per group. Data are expressed as means ± standard
deviation dilution, which gives the half maximal value.
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Figure 8
Bone destruction is prevented by interleukin (IL)-4 and IL-4/prednisolone
treatment. (a) Severe bone destruction in patella and femur in knee
joint of vehicle-treated animal. (b) Almost no bone degradation was
noted after treatment with IL-4/prednisolone (1 µg per day/0.05 mg per
kg). (c) Bone destruction in femur of a vehicle-treated animal at higher
magnification. Osteoclasts, large multinuclear cells, located at the site
of bone destruction (arrows). (d) No osteoclast-like cells were found in
IL-4 (1 µg/day) treated animals. For treatment details see Fig. 4.
S, synovium; B, bone; BM, bone marrow. Original magnifications
×200 (a, b), ×400 (c, d).
disease, whereas IL-1 is the dominant cytokine, not only
at the onset, but also in the progression of the arthritis and
the concomitant cartilage destruction. Further support for
the critical role of IL-1 is provided by the absence of colla-
gen arthritis in IL-1β-deficient mice, and the marked
reduction of this arthritis in ICE-deficient mice as well as
in normal mice treated with IL-1β-converting enzyme
inhibitors [40,41]. Moreover, reduced onset of arthritis was
noted in TNF-receptor-deficient mice, but once a joint
was afflicted the arthritis progressed to full-blown expres-
sion and cartilage destruction, again emphasizing that
TNF is important in onset, but is not the dominant
cytokine in progression and tissue destruction [42].
In recent studies, it was clearly demonstrated that onset of
CIA is under stringent control of IL-4 and IL-10, because
blockade of both IL-4 and IL-10 by the use of antibodies
accelerated disease onset [26]. Furthermore, treatment of
established murine CIA with low-dose IL-4 showed no
suppressive effect on disease activity and joint pathology.
Interestingly, combination of low-dose IL-4 and IL-10
appeared to have more potent anti-inflammatory effects,
and resulted in protection against cartilage pathology [26].
Systemic treatment of murine CIA with high-dose IL-4
(3µg/day) during the immunization stage delays onset as
well as reduces severity. When IL-4 administration was
terminated, however, disease expression and activity
rapidly accelerated and was indistinguishable from that in
the vehicle-treated control group [34]. Systemic IL-4
treatment of streptococcal cell wall arthritis in rats resulted
in suppression of disease activity, and ameliorated the
chronic destructive process leading to decreased lesions
[33]. This was associated with enhanced levels of IL-1Ra,
the natural inhibitor of IL-1, which is in accord with obser-
vations in the present study and with studies in humans
systemically treated with IL-4 [43]. However, it is not
likely that the twofold increment in serum IL-1Ra levels,
found after IL-4 exposure, is sufficient to suppress CIA.
As previously mentioned, blockade of IL-1 by anti-IL-1
antibodies or very high-dose IL-1Ra completely sup-
pressed CIA and lead to full protection against joint
pathology [17,18,25]. Whether IL-4 acts locally or systemi-
cally is at present unknown. Further experiments on
biodistribution of IL-4 are needed to resolve this issue.
IL-4 levels are virtually undetectable in arthritic tissue of
RA patients, suggesting that the disease is either a selec-
tive Th1 process or is not driven at all by T cells. An alter-
native explanation could be the fact that IL-1α and IL-1β
specifically inhibit IL-4 synthesis by T cells [44]. Other
proinflammatory cytokines, such as TNF-α, IL-6 and
IL-12 did not decrease IL-4 production, indicating the
pivotal role of IL-1 in RA. It is known that IL-4 has a sup-
pressive effect on Th1 activity and is a crucial factor in dif-
ferentiation of naïve T cells into the Th2 phenotype. This
suppression has been suggested to be due to the
inhibitory effect of IL-4 on IL-12 generation by antigen-
presenting cells and macrophages [7]. IL-12, on the other
hand, is a potent stimulator of the generation of Th1 cells.
Analysis of anticollagen type II antibodies revealed that
systemic IL-4 treatment did not alter the balance of
IgG2a/IgG1 antibodies, indicating no suppressive effect on
the Th1 immune response. Total anticollagen type II anti-
body levels were lower in both IL-4 (1µg/day) and
IL-4/prednisolone treated animals when compared with
the vehicle group. We have previously found that anticol-
lagen type II antibody levels rapidly increased after onset
of CIA and reached the highest levels after 7 days (Joosten
LAB, unpublished data). IL-4 treatment arrested the
development of high anticollagen type II antibody levels
after onset and did not alter IgG2a/IgG1 balance.
Cartilage alterations were screened for by histology as well
as COMP levels in sera of mice at the end of the experi-
ments. COMP is a prominent component of articular carti-
lage. In a process affecting cartilage turnover, fragments
are released and eventually reach the circulation. Thus,
serum levels may be used as a marker of generalized carti-
lage turnover [44,45]. More recent studies [46,47] have
demonstrated the production of COMP by activated syn-
ovial cells and synovial tissue of RA and osteoarthritis
patients. Although the relative contribution to serum
levels is not firmly established, important information has
been obtained from studies of collagen arthritis in rats.
Thus, increased serum COMP levels are seen at time
points when erosive changes appear in cartilage, whereas
in early stages with marked inflammation in the synovium
no increased COMP levels are seen [37,38] (Larsson E,
Saxne T, unpublished data). Furthermore, serum COMP
levels are reduced to normal in murine CIA after treat-
ment with IL-1-blocking antibodies, in correspondence
with a marked suppression of the cartilage lesion as
viewed histologically [17]. Thus, evidence so far indicates
that changes in serum COMP relate to changes in the car-
tilage turnover. In accord with these findings, low-dose
IL-4/prednisolone treatment did not suppress disease
activity, largely reflecting synovitis, but clearly reduced
serum COMP levels. Histology interestingly revealed that
serum COMP levels correlated more with cartilage ero-
sions than with loss of matrix proteoglycans, which is a
reversible process.
Recently, it was shown that expression of neo-epitope
VDIPEN correlated with marked cartilage erosions during
experimental arthritis. This neoepitope is formed by pro-
teolytic cleavage of aggrecan by matrix metalloproteinases
(MMPs). VDIPEN expression reflects MMP-3 (eg
stromelysin) activity and it colocalized with collagen
breakdown epitopes, indicating severe cartilage damage
by MMPs [48,49]. It was demonstrated that IL-4 down-
regulates both stromelysin and collagenase synthesis and
thereby contributed to inhibition of cartilage destruction
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[11,12,50]. Thus, reduction of cartilage destruction found
after IL-4 treatment may well be due to a lower produc-
tion of MMPs and/or inhibition of their activity. The fact
that IL-4 treatment did not protect against proteoglycan
loss does suggest that IL-4 has no major suppressive effect
on aggrecanase. In a previous study [51] we showed that
early proteoglycan loss is mediated by aggrecanase,
whereas erosive, late destruction is linked to stromelysin.
Control of bone destruction is a most challenging objec-
tive in treatment of RA. In areas of tumour-like synovial
tissue, erosion of subchondral and cortical bone is
common, leading to the characteristic erosions seen on
radiography. Osteoclasts can be seen in the areas of bone
destruction during CIA. It has been reported that IL-4
inhibits bone resorption by inhibition of osteoclast devel-
opment and activity in vitro [13,14]. Here, we report for
the first time that systemic IL-4 treatment of established
CIA markedly reduced bone erosions, examined by radi-
ographic analysis and histopathology. Neither bone
destruction nor osteoclasts were noted in arthritic knee
joints of animals treated with high-dose IL-4, indicating
decreased formation of these cells. IL-4 furthermore
downregulates IL-1, IL-6, TNF-α and prostaglandin E2
production in several cell types that play a role in the
resorption process of the bone. Interestingly, blocking
studies with neutralizing antibodies directed against IL-4
in CIA indicated that the endogenous cytokine inhibited
bone destruction. In animals treated with anti-IL-4, bone
destruction determined by radiographic analysis was
aggravated compared with that in vehicle-treated animals
(data not shown).
Glucocorticoids are potent and commonly accepted anti-
inflammatory agents, but the major drawback on contin-
ued usage in arthritis is the severe negative effect on the
bone. More recent studies on the mechanism of action
revealed strong downregulation of macrophage production
of the proinflammatory cytokines TNF-α and IL-1,
related to enhanced IκBα synthesis. Intriguingly, over a
large dose range steroids not only inhibit TNF and IL-1,
but also reduce the production of IL-1Ra and regulatory
cytokines such as IL-4 and IL-10 [52]. This suggests that
the net effect in joint inflammation is impaired by the lack
of the protective cytokines, which inhibit TNF/IL-1
production as well as induce potent upregulators of
scavengers such as soluble receptors for TNF and IL-1,
and IL-1Ra [8,9,53]. Moreover, IL-4 powerfully reduces
inducible nitric oxide synthase expression, thereby coun-
teracting the suppressive effect of IL-1 on chondrocyte
proteoglycan synthesis, which is mainly nitric oxide medi-
ated. Evidence for the latter was provided in in vitro
studies with nitric oxide inhibitors. In further support of a
role in vivo, we recently demonstrated that IL-1 failed to
inhibit chondrocyte proteoglycan synthesis in inducible
nitric oxide synthase deficient mice [54].
The present data clearly demonstrates the synergistic
effect of combination therapy of low-dose prednisolone
and IL-4. Low-dose IL-4 was without suppressive effect
on clinical disease activity, which is in accord with previ-
ous studies [39]. However, when combined with pred-
nisolone the progression of CIA was completely arrested.
Furthermore, synergistic suppression of cartilage destruc-
tion was demonstrated by lowered serum COMP levels,
which was also reflected by histology. Only combined
therapy with high-dose IL-4 and prednisolone was able to
suppress the influx of inflammatory cells in joint tissues
and reduce the loss of matrix proteoglycans.
In conclusion, IL-4 might offer an alternative cartilage-
and bone-protective therapy that is complementary to
TNF/IL-1 inhibitors. Its limited effect on the inflamma-
tory process warrants combination with other therapeutic
modalities. The present data suggest that combination
with prednisolone at low dosages provides an intriguing
option. In accord with earlier observations of both
IL-10/prednisolone and IL-4/IL-10 synergy [26,39], it
must be considered that a cocktail of IL-4, IL-10 and low-
dose glucocorticosteroids or glucocorticoids might be an
even more efficacious therapy for human RA.
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